0001104659-26-053102
SEC filingTELA Bio announced preliminary Q1 2026 revenue of $19.0 million and major Board changes including Chairman Doug Evans not standing for re-election and appointments of new directors effective post-2026 Annual Meeting.
The preliminary unaudited revenue of $19.0 million for the quarter ended March 31, 2026, provides an early indicator of top-line performance but carries significant caveats: it is management's estimate prior to quarter-end close, unaudited by KPMG LLP, and not a full GAAP financial statement. Investors should await the Form 10-Q for finalized results, as adjustments could materially alter this figure and exclude key details on expenses, profitability, or cash position. No comparatives or drivers are disclosed in the filing. Concurrently, Item 5.02 signals substantial Board refreshment ahead of the June 9, 2026 Annual Meeting. Chairman Doug Evans' retirement, alongside resignations of three directors (Azarbarzin, Burgess, O’Brien), removes experienced members without disagreements on company matters. Incoming leadership introduces deep MedTech expertise: Joseph Capper (ex-CEOs of MiMedx, BioTelemetry) as non-independent Chairman; independent directors Guido Neels (ex-Guidant COO, EW Healthcare), Guy Nohra (Alta Partners co-founder), and Paul Thomas (ex-LifeCell CEO). Their committee roles and standardized equity/cash compensation align with the non-employee director policy under the 2019 Equity Incentive Plan. This overhaul may signal strategic shifts in governance and oversight, potentially influencing compensation, audit, and nominations amid revenue trajectory scrutiny.